TRIUMEQ 5 mg/60 mg/30 mg, dispersible tablet 90 tablets
Active ingredients: Abacavir, Dolutegravir, Dolutegravir sodium, Lamivudine, Abacavir sulfate
Commercialized according to BDPMDispensing in France: Prescription only
Dispersible tablet90 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TRIUMEQ 5 mg/60 mg/30 mg, comprimé dispersible
- Pharmaceutical form
- comprimé dispersible
- Route of administration
- orale
- Presentation description
- 1 flacon polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 90 comprimés + 1 godet doseur
- Marketing authorisation holder
- VIIV HEALTHCARE (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 23 Nov 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63892609CIP73026653CIP133400930266533Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LAMIVUDINEcomprimé | 30 mg · un comprimé | SA |
| ABACAVIRcomprimé | 60 mg · un comprimé | FT |
| DOLUTÉGRAVIR SODIQUEcomprimé | — | SA |
| DOLUTÉGRAVIRcomprimé | 5 mg · un comprimé | FT |
| SULFATE D'ABACAVIRcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.